SILO PHARMA, INC. Financing Receivable, Allowance for Credit Loss
SILO PHARMA, INC. (SILO) had Financing Receivable, Allowance for Credit Loss of $69.60 thousand as of 2024-06-30, per its 10-Q filed 2024-08-13.
Discontinued › Balance Sheet › Assets › Financing Receivable, after Allowance for Credit Loss
us-gaap:FinancingReceivableAllowanceForCreditLosses · last filed 2024-08-13
- 2024-06-30: Financing Receivable, Allowance for Credit Loss $69.60K.
- 2024-03-31: Financing Receivable, Allowance for Credit Loss $69.60K.
- 2023-12-31: Financing Receivable, Allowance for Credit Loss $69.60K.
- 2022-09-30: Financing Receivable, Allowance for Credit Loss $35.50K.
| Period end | Financing Receivable, Allowance for Credit Loss | Financing Receivable, Allowance for Credit Loss as first filed |
|---|---|---|
| 2024-06-30 | $69.60K 10-Q · filed 2024-08-13 | |
| 2024-03-31 | $69.60K 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $69.60K 10-Q · filed 2024-08-13 | |
| 2022-09-30 | $35.50K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $35.50K 10-Q · filed 2022-08-01 | |
| 2022-03-31 | $35.50K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $55.50K 10-K · filed 2023-03-24 | $71.50K 10-K · filed 2022-03-28 |
| 2021-09-30 | $113.00K 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $150.50K 10-Q · filed 2021-08-13 | |
| 2021-03-31 | $196.50K 10-Q · filed 2021-05-17 | |
| 2020-12-31 | $196.50K 10-K · filed 2022-03-28 | |
| 2020-09-30 | $140.00K 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $50.00K 10-Q · filed 2020-08-14 | |
| 2020-03-31 | $50.00K 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $50.00K 10-K/A · filed 2021-05-17 | |
| 2019-09-30 | $50.00K 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $50.00K 10-Q · filed 2019-08-13 | |
| 2019-03-31 | $50.00K 10-Q · filed 2019-05-14 | |
| 2018-12-31 | $50.00K 10-K · filed 2020-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |